Osvaldo Flores Biography and Net Worth

Osvaldo (Lalo) Flores is Chief Executive Officer of Century Therapeutics. He was previously Vice President of R&D and Entrepreneur-in-Residence with Janssen (Johnson & Johnson). He assumed those roles after completing the acquisition and integration of Novira Therapeutics, where he was a co-founder, the President and Chief Scientific Officer. Prior to Novira, Lalo was a department head at Merck & Co., where he led drug discovery and development programs across diverse therapeutic areas including antiviral, oncology and metabolic disease. He started his R&D career at Tularik Inc., establishing key elements of the antiviral drug discovery platform. Lalo received his PhD in Biochemistry and Molecular Biology from Rutgers University and was a postdoctoral Fellow at the Salk Institute.

How do I contact Osvaldo Flores?: The corporate mailing address for Flores and other Century Therapeutics executives is , , . Century Therapeutics can also be reached via phone at 267-817-5790 and via email at [email protected]. Learn More on Osvaldo Flores' contact information.
Has Osvaldo Flores been buying or selling shares of Century Therapeutics?: Osvaldo Flores has not been actively trading shares of Century Therapeutics over the course of the past ninety days. Learn More on Osvaldo Flores' trading history.
Who are Century Therapeutics' active insiders?: Century Therapeutics' insider roster includes Eli Casdin (Director), and Osvaldo Flores (Pres). Learn More on Century Therapeutics' active insiders.
Are insiders buying or selling shares of Century Therapeutics?: During the last year, Century Therapeutics insiders bought shares 1 times. They purchased a total of 35,000 shares worth more than $17,500.00. During the last year, insiders at the sold shares 17 times. They sold a total of 81,510 shares worth more than $39,411.72. The most recent insider tranaction occured on November, 19th when CEO Brent Pfeiffenberger bought 35,000 shares worth more than $17,500.00. Insiders at Century Therapeutics own 5.0% of the company. Learn More about insider trades at Century Therapeutics.
Information on this page was last updated on 11/19/2025.

Osvaldo Flores Insider Trading History at Century Therapeutics

Osvaldo Flores Buying and Selling Activity at Century Therapeutics

Century Therapeutics Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $0.53

$0.51

$0.54

50 Day Range

MA: $0.54

$0.46

$0.62

2 Week Range

Now: $0.53

$0.34

$1.74

Volume

970,512 shs

Average Volume

966,780 shs

Market Capitalization

$45.95 million

P/E Ratio

N/A

Dividend Yield